The superior effects of obinutuzumab seen in the laboratory have been confirmed in clinical trials and, in 2013, the drug was the first drug to be awarded Breakthrough Therapy Designation by the ...

In this video, Iberia Romina Sosa, MD, PhD, discusses the results of a study presented at ASH Annual Meeting and Exposition, which examined the use of obinutuzumab in patients with thrombotic ...

Reply to: “Breast Cancer Screening Interval: Effects of Proportions and Biases on Benefits” and “Annual Versus Biennial Mammographic Screening” The article by Davids et al entitled “A Phase II Study ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

A third arm evaluating acalabrutinib-venetoclax plus intravenous obinutuzumab (Gazyva) also topped chemoimmunotherapy when it came to PFS, with a 3-year rate of 83.1% (HR 0.42, 95% CI 0.30-0.59 ...

In patients with chronic lymphocytic leukemia (CLL) who did not previously receive treatment, a combination of Imbruvica (ibrutinib) plus venetoclax chemotherapy showed promising outcomes compared ...